The Musk premium is now a spreadsheet line item—and secondary buyers are treating his startups like lottery tickets with better odds.
The Summary
- Neuralink is trading at up to $42 billion on secondary markets, nearly 5x its $9 billion valuation from last year's funding round
- Some buyers are bidding nearly $60 billion for shares, driven by post-SpaceX IPO Musk mania—SpaceX now trades at $1.7 trillion
- One VC reports limited partners demanding Neuralink shares "at any price," while others refuse to touch the valuations
The Signal
Neuralink hasn't announced a breakthrough product. It hasn't scaled to thousands of implants. It's still primarily a research-stage brain-computer interface company with a handful of human trials. Yet secondary market transactions are pricing it between $29 billion and $42 billion, with some buyers willing to go as high as $60 billion.
This isn't a valuation. It's a Musk tax.
The math starts making sense when you map the incentive structure. Musk has a documented habit of interweaving his companies—X and xAI investors eventually got SpaceX shares through acquisitions. After SpaceX's IPO minted a $1.7 trillion market cap, private investors learned the lesson: early access to any Musk entity is a potential backdoor to the next one. You're not buying Neuralink. You're buying optionality on whatever Musk builds next and decides to merge, acquire, or cross-pollinate.
"One venture investor said that several of their limited partners have been asking to buy Neuralink shares 'at any price.'"
Here's what that appetite reveals about the agent economy: investors are pricing in a future where brain-computer interfaces aren't niche medical devices but infrastructure for human-AI collaboration. Neuralink's current product—a chip that lets paralyzed patients control computers with their thoughts—is impressive but narrow. The $42 billion bet is on scale. On BCIs becoming the input layer for a world where your agents need faster instructions than typing or talking can provide.
The secondary market frenzy also exposes a structural shift in how private capital flows. Traditional venture rounds happen when companies need money. Secondary markets happen when investors need access. Neuralink doesn't appear to be raising. But demand for shares is so high that employees and early backers are cashing out at 5x in under 18 months. Private markets research provider Caplight is tracking the range, but there's no consensus—some buyers see $30 billion as reasonable, others see $60 billion as cheap.
Key dynamics driving the spread:
- The SpaceX precedent: Investors who passed on early SpaceX access watched it 100x. FOMO is structural now.
- Cross-company liquidity: Musk's companies don't stay separate. Owning one can mean owning three later.
- BCI as agent interface: If AI agents become ubiquitous, direct neural input could be the next keyboard replacement.
The risk is obvious. These aren't public market prices with continuous liquidity. They're one-off transactions between desperate buyers and opportunistic sellers. If Neuralink stumbles—regulatory delays, safety issues, Musk distraction—there's no floor. Secondary buyers could be holding illiquid shares in a $9 billion company they paid $42 billion to access.
The Implication
Watch how Neuralink's actual product development maps against this valuation. If the company announces commercial partnerships, FDA approvals for broader use cases, or integration with Musk's AI stack at xAI, the $42 billion starts looking justified. If it stays in slow-moving clinical trials while secondary prices keep climbing, you're watching a bubble inflate in real time.
For builders: the Musk playbook is now explicit. Interweave your companies. Give early investors reasons to believe one bet gets them three. For everyone else: be cautious about secondary markets pricing in science fiction. Brain-computer interfaces are real. $42 billion for a pre-revenue medical device company is speculative faith.